SIHUAN PHARM (00460.HK): Miao Guili resigns as executive director and CFO, Che Yuxuan appointed non-executive director and Song Xiaomi appointed CFO
NewTimeSpace News: On 26 August 2026, Sihuan Pharmaceutical Holdings Group Ltd. (stock code: 00460) announced that, to focus on personal career development, Ms. Miao Guili has resigned as executive director, deputy chief executive officer and chief financial officer of the Company, and has ceased to serve as co-chairman of the risk management committee of the board, with effect from 26 August 2026. Ms. Miao confirmed that there is no disagreement with the board and no matters relating to her resignation that need to be brought to the attention of the shareholders and the Stock Exchange.
On the same day, Mr. Che Yuxuan was appointed as a non-executive director and a member of the risk management committee of the board. Mr. Che, aged 25, currently serves as assistant to the chairman of Xuanzhu Biopharmaceutical Co., Ltd. (stock code: 02575.HK), primarily responsible for assisting the chairman in coordinating strategic operations, and previously worked as a data science researcher at Massachusetts General Hospital and in marketing and sales at Sanofi Pasteur; he holds a bachelor's degree in biology from the University of Washington. Mr. Che is the son of Dr. Che Fengsheng, an executive director, chairman of the board and controlling shareholder of the Company. His appointment letter runs from 26 August 2026 to 25 August 2029, subject to retirement by rotation and re-election at the next annual general meeting in accordance with the Company's articles of association, and he will not receive any director's fee as a non-executive director.
On the same day, Ms. Song Xiaomi was appointed as chief financial officer of the Company. Ms. Song, aged 59, is the director of the Group's planning and finance center, with extensive experience in financial management, strategic operations and compliance system development in the pharmaceutical industry; she previously served as financial controller and operations director of Beijing Kangen Pharmaceutical Co., Ltd. (603590.SH), and held positions including director of operations and information management, operations director, sales control manager and finance manager at Bayer Healthcare Co., Ltd. She holds a master's degree in accounting from Deakin University (Australia) and is a Senior Certified Practicing Accountant of Australia and a Chinese intermediate accountant.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
